AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04604457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative care contacts primary care
Description: Palliative care specialist reaches out to primary care to recommend a palliative care consult. If the primary care provider agrees, he/she will write an order for a palliative care consult.
Study NCT00715793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: In Part I patients will be treated on a standard 3+3 phase I dose-escalation design starting at 0.075 mg/kg until a decitabine dose level of 0.15 mg/kg is reached, or, in case unacceptable toxicities are observed, at the maximum tolerated dose (Phase II recommended dose). Decitabine will be administered at the specified dose level, intravenously, daily 5 days a week for the first 2 weeks of a 6-week cycle.
Study NCT00715793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide is available in 25 mg and 100 mg tablets that will be administered orally; doses will be rounded to the nearest 25 mg. Temozolomide will be administered orally at 75 mg/m2 daily for 4 weeks starting on week 2 of a 6-week cycle.
Study NCT00715793 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Fine needle aspirates (FNA) and/or core biopsies of tumor samples will be obtained from consenting patients with accessible, evaluable disease, on days 1, 8, 15, and 29 of the first cycle and when patients go off study. Biopsies are optional in Phase I and required for all consenting subjects in Phase II.
Study NCT01276080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: 10 mg tablets
Study NCT03623958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Image guided Video-Assisted Thoracic Surgery (VATS) resection
Description: Image guided placement of a fiducial consisting of a needle directed placement of a T-Bar next to the target lesion in order to lead the surgeon to the lung region to be removed
Study NCT03623958 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Video-Assisted Thoracic Surgery
Description: Standard of Care Video-Assisted Thoracic Surgery (VATS) resection
Study NCT03033797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MoviLetrando
Description: Half of the participants will play two different levels of the Game MoviLetrando, two minutes each.
Study NCT01824095 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement
Study NCT01824095 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary supplement
Study NCT00719056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Description: The selected dose was 10mg/kg and it was given intravenously by a catheter inserted under aseptic conditions in a forearm vein within 15 minutes; it was diluted in one 5% glucose solution of a 50 ml final volume
Study NCT03033797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MoveHero
Description: Half of the participants will play 2 minutes of the game MoveHero.
Study NCT04466163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Schema Therapy and the Healthy Adult
Description: The protocol 'Schematherapy and the Healthy Adult' (ST-HA, Broersen \& Claassen, 2019) is a direct intervention meant to strengthen patients' healthy adult functioning by developing compassion and care for well-being in the face of (childhood) adversity.
Study NCT00719407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythropoietin
Description: 250 U/kg/dose x 6 doses (n=3); 500 U/kg/dose x 6 doses (n=6); 1,000 U/kg/dose x 6 doses (n=7) 2,500 U/kg/dose x 6 doses (n=8)
Study NCT03952793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: extended biopsy
Description: Additional sample are performed during a biopsy to provide tumor tissues for the organoid technique development
Study NCT02165111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin A
Study NCT02165111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sterile saline solution
Study NCT02806479 — intervention group
Intervention type: OTHER
Intervention: Observational: Arrhythmogenic Substrate
Study NCT00094653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDX-010 (anti-CTLA4) monoclonal antibody
Description: 3mg/kg (intravenous \[iv\] infusion over 90 minutes), every 3 weeks for 4 doses
Study NCT00094653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDX-010 (anti-CTLA4) monoclonal antibody
Description: 3mg/kg (intravenous \[iv\] infusion over 90 minutes), every 3 weeks for 4 doses
Study NCT00094653 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MDX-1379 (gp100) Melanoma Peptide Vaccine
Description: 2mL (2 subcutaneous injections of 2 mL each, 1 to each thigh), every 3 weeks for 4 doses.
Study NCT00094653 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDX-1379 (gp100) Melanoma Peptide Vaccine
Description: 2mL (2 subcutaneous injections of 2 mL each, 1 to each thigh), every 3 weeks for 4 doses.
Study NCT01836094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue (USP grade, 280mg oral)
Study NCT01836094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, one time
Study NCT01153685 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluviral®
Description: Intramuscular injection, one dose
Study NCT00330551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Risperidone
Description: Patients will be treated with oral risperidone daily, with the dosage determined by treating psychiatrist.
Study NCT00330551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone in Long-Acting Injectable Form (Consta)
Description: Participants will take a 25 mg dosage of injectable risperidone (Risperidone in Long-Acting Injectable Form (Consta)) once every 2 weeks. Dosage will be adjusted if needed.
Study NCT04630522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: JMT103- 120 mg SC Q4W
Description: JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 4-week cycle.
Study NCT04630522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: JMT103- 120 mg SC Q8W
Description: JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 8-week cycle.
Study NCT04630522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: JMT103- 180 mg SC Q8W
Description: JMT103 is administered subcutaneously at a dose of 180 mg on day 1 of each 8-week cycle.
Study NCT04630522 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Calcium Dietary Supplement: Vitamin D
Description: Calcium is given orally at a dose of 500 mg at least, once daily. Vitamin D is given orally at a dose of 400 IU at least, once daily.
Study NCT00719056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: β-lactams or ciprofloxacin
Description: Multiple doses for up to six consecutive days
Study NCT04698707 — intervention group
Intervention type: OTHER
Intervention: Vascularized lymph node flap transfer
Description: Patients who have received VLNT as their primary treatment but with minimal improvement
Study NCT04698707 — intervention group
Intervention type: OTHER
Intervention: Patients without prior lymphedema surgery
Description: Patients without prior lymphedema surgery
Study NCT04707014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Rapid conversational hypnosis
Study NCT04707014 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention-distracting techniques
Description: i-pad with movies, games and music
Study NCT04466436 — intervention group
Intervention type: OTHER
Intervention: tryptophan
Description: measurement of tryptophan in serum
Study NCT02130648 — intervention group
Intervention type: OTHER
Intervention: A sampling of blood
Description: A sampling of blood de 14 ml
Study NCT04269031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2373 subcutaneous injection
Description: Randomised subjects will receive a single ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5 and dose 6).
Study NCT04269031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Randomised subjects will receive a single ascending dose of placebo (saline solution) by SC injection.
Study NCT03015207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194-0499
Study NCT03015207 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00447265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 1.) Immune suppressant. 2.) Tumor necrosis factor (TNF) inhibitor.
Study NCT00447265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lupus Treatment- Standard of Care
Description: Individualized standard of care treatment for lupus with corticosteroids and with mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA)
Study NCT00447265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lupus Treatment- Standard of Care
Description: Individualized standard of care treatment for lupus with corticosteroids and with mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA)
Study NCT00447265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00056537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABR-217620
Description: Starting dose: 0.5 mcg/kg; subsequent doses: individual, based on pre-treatment level of anti-SEA/E-120, body weight, and toxicities observed in prior patients on study; IV; one bolus injection each day for 5 consecutive days; up to 3 cycles
Study NCT02658578 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PNS
Description: Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator. In sham PNS, the median, ulnar and radial nerves will not be actively stimulated.
Study NCT02658578 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PNS
Description: Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator. In sham PNS, the median, ulnar and radial nerves will not be actively stimulated.
Study NCT02978690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Solution for infusion
Study NCT01557075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin (High dose statin treatment)
Description: Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program~* Atorvastatin 40 mg daily for 12 months after randomization
Study NCT01871597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmonary Artery Energy Seal
Description: Pulmonary artery energy seal devices such as: Ligasure, Harmonic scalpel, Enseal, Thunderbeat, Unipolar and Conventional bipolar Cautery, metal clip or Hem-o-lok clip will be used to seal the artery(ies)
Study NCT04737499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CASCADe
Description: Culturally tailored diabetes self-management and education sessions with mHealth integration
Study NCT01384916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 2x weekly
Study NCT01384916 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living Workshop
Description: 2x weekly
Study NCT01256814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SystemCHANGE-HIV
Description: SystemCHANGE, is based on social ecological theory and focuses on redesigning the family environment and daily routines that are linked to health behavior. This framework emphasizes context and specifies that change is best accomplished by: identifying a measurable goal, examining the system processes surrounding attainment of that goal, listing several ideas that may improve the system, engaging in a series of experiments to test the best ideas to improve the process, implementing the most successful ideas based on data from the experiments, and monitoring the system to maintain the gains. The SystemCHANGE-HIV intervention works to help participants make small environmental changes made in family daily routines that will eventually construct an environment.
Study NCT01256814 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SystemCHANGE-HIV
Description: SystemCHANGE, is based on social ecological theory and focuses on redesigning the family environment and daily routines that are linked to health behavior. This framework emphasizes context and specifies that change is best accomplished by: identifying a measurable goal, examining the system processes surrounding attainment of that goal, listing several ideas that may improve the system, engaging in a series of experiments to test the best ideas to improve the process, implementing the most successful ideas based on data from the experiments, and monitoring the system to maintain the gains. The SystemCHANGE-HIV intervention works to help participants make small environmental changes made in family daily routines that will eventually construct an environment.
Study NCT01979822 — intervention group
Intervention type: OTHER
Intervention: PH patients with LenusPro pump
Description: Observation/measurement of complications in PH patients with LenusPro pump in the frist six month after implantation of pump
Study NCT04380688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib administered orally
Study NCT01894750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group-based skill building self-care program
Study NCT00725127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: 100 mg/day upon awakening for five years
Study NCT00725127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: 100 mg/day at bedtime for five years
Study NCT01112163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced external counter pulsation
Description: While an individual is undergoing ECP, they have pneumatic stockings (also known as cuffs) on their legs and are connected to telemetry monitors that monitor their heart rate and rhythm.The cuffs should ideally inflate at the beginning of diastole and deflate at the beginning of systole. During the inflation portion of the cycle, the calf cuffs inflate first, then the lower thigh cuffs and finally the upper thigh cuffs. Inflation is controlled by a pressure monitor, and the cuffs are inflated to about 300 mmHg.
Study NCT03542721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5515
Description: Crataegi ethanol extract, Garlic oil, Ginkgo leaf extract, Melissa folium extract (three times a day)
Study NCT03542721 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of DA-5515
Description: Placebo (three times a day)
Study NCT03621683 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blood rich plasma platelets
Description: Injection of blood rich platelet into the ovaries.
Study NCT03621683 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood rich plasma platelets
Description: Injection of blood rich platelet into the ovaries.
Study NCT03621683 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidant therapy
Description: Antioxidants:~Q10, DHEA, Vitamina E, Vitamin C, Omega 3
Study NCT03621683 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant therapy
Description: Antioxidants:~Q10, DHEA, Vitamina E, Vitamin C, Omega 3
Study NCT02468037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Description: Patients donate blood until tissue iron levels are in the lowest quartile of normal.
Study NCT01557075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin (High dose statin treatment)
Description: Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program~Pravastatin 20mg daily for 12 months after randomization
Study NCT00572507 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MonoMax®
Description: Abdominal wall closure with ultra-longterm absorbable monofilament suture after primary median laparotomy
Study NCT04002856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Profhilo®
Description: Profhilo® (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 2.25 ml non-pyrogenic pre-filled syringe, containing 2 ml of 3.2% hyaluronic acid for intradermal use (32 mg H-HA + 32 mg L-HA dissolved in 2 ml of saline buffered sodium chloride
Study NCT04933188 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Myocardial work was estimated from left ventricular pressure-strain loop derived from speckle tracking echocardiography and non-invasive brachial artery cuff pressure
Description: Baseline and follow-up examination of echocardiography is to be performed on study subjects.
Study NCT04303598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FNC
Description: 3mg, 1 tablet，QD
Study NCT04303598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3TC
Description: 300mg, 1 tablet，QD
Study NCT02800148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelaic acid foam
Study NCT02454413 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: denture brushing with water and soap
Description: denture brushing with water and soap
Study NCT02454413 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: denture brushing with water and soap
Description: denture brushing with water and soap
Study NCT02454413 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonic denture cleaning
Description: ultrasonic denture cleaning
Study NCT02454413 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: ultrasonic denture cleaning
Description: ultrasonic denture cleaning
Study NCT02454413 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cleansing tablet
Description: addition of a cleansing tablet to the water in which the dentures are stored overnight
Study NCT04622540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External biliary drainage
Description: Application of external biliary drainage through duct-to-duct anastomosis
Study NCT02991651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRX4204
Description: RXR agonist
Study NCT02991651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: inhibitor of phosphorylation of the tyrosine kinase associated with the epidermal growth factor receptor
Study NCT03352804 — intervention group
Intervention type: OTHER
Intervention: Screening of MDR Bacteriae
Description: questionnaire will be filled by every patient
Study NCT02800148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelaic acid foam
Study NCT02800148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azelaic acid foam - Placebo
Study NCT02052479 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT)
Study NCT03970473 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary recruitment maneuver (PRM)- 30 cm H2O
Description: Pulmonary recruitment maneuver (PRM) consists of five manual pulmonary inflations where each positive pressure inflation will be performed for 5 s at a maximum pressure of 30 cm H2O in the semi-fowler position (30° head-of-bed elevation ). PRM is performed after LS when the main umbilical port is remaining and aims to remove the remaining gas following LS.
Study NCT03970473 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary recruitment maneuver (PRM)- 15 cm H2O
Description: Pulmonary recruitment maneuver (PRM) consists of five manual pulmonary inflations where each positive pressure inflation will be performed for 5 s at a maximum pressure of 15 cm H2O in the semi-fowler position (30° head-of-bed elevation ). PRM is performed after LS when the main umbilical port is remaining and aims to remove the remaining gas following LS.
Study NCT01833403 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hyperinsulinemic-euglycemic clamp
Description: Subject will received 6,6 2H2 Glucose prior and during a 4 hr hyperinsulinemic-euglycemic clamp to characterize hepatic insulin resistance prior to bariatric surgery~--------------------------------------------------------------------------------
Study NCT03275558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Axitinib 1 MG
Description: Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.~Subjects take a nasal spray BID at a single dose in each nostril (approximately at the same time of day) for 7 weeks or unacceptable toxicity or other adverse events.
Study NCT03275558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib 5 MG
Description: Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.